Study Summaries

- Adding bevacizumab to gemcitabine and carboplatin significantly improves PFS but no difference in OS in platinum-sensitive recurrence

Continuing bevacizumab beyond progression combined with chemotherapy significantly improves progression-free survival in patients with platinum-sensitive recurrent ovarian cancer compared to standard chemotherapy alone, but no OS benefit

The addition of bevacizumab to standard chemotherapy (paclitaxel and carboplatin) improves PFS significantly and may offer a clinically meaningful improvement in OS.

Maintenance olaparib provides a clinically meaningful improvement in OS for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation. The 7-year follow-up data support its use for long-term remission.

Docetaxel-carboplatin is similar to paclitaxel-carboplatin in terms of progression-free survival and overall response but has significantly less neurotoxicity. It represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.

Weekly paclitaxel did not significantly extend progression-free survival (PFS) compared to every-3-week paclitaxel overall.

IP administration of cisplatin and paclitaxel significantly improves both progression-free and overall survival in patients with optimally debulked stage III ovarian cancer compared to standard IV therapy, despite increased toxicities.

The combination of carboplatin and paclitaxel is not inferior to cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer. Carboplatin plus paclitaxel results in less toxicity and is easier to administer.

Primary chemotherapy followed by delayed surgery is non-inferior to primary surgery followed by chemotherapy in women with advanced ovarian cancer, with reduced surgical morbidity and mortality.